MIRA INFORM REPORT

Report Date :

08.01.2011

IDENTIFICATION DETAILS

Name :	NOVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA

Registered Office :	Via al Mulino 22, 6814 Cadempino

Country :	Switzerland

Year of Establishment :	2003

Com. Reg. No.:	514.3.027.384-5 / 714472

Legal Form :	Company limited by shares

Line of Business :	Wholesale of Consumer goods

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended

Status :	Undetermined

Payment Behaviour :	Unknown

Litigation :	---

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – June 30, 2010

Country Name

Previous Rating

(01.04.2010)

Current Rating

(30.06.2010)

Switzerland

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Company name

NOVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA

Operating address

Via al Mulino 22

6814 Cadempino

Switzerland/CH

Telephone: 091 9676221

Profile

Established: 2003

Line of Business: Consumer goods wholesale

Industry Division: Wholesale trade

Industry-code (NACE): 4675 Wholesale of chemical products

4646 Wholesale of pharmaceutical goods

Banks: unknown

Operational Figures

Coverage: Company

Employees: 3

Company Register

Company No: 514.3.027.384-5 / 714472

Legal form: Company limited by shares

Legal status: active

Responsible Register: Registro di commercio del Cantone Ticino

Entry Deleted Name

active OVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA

Entry Deleted Legal domicile

active dempino, Switzerland

Entry Deleted Address

active a al Mulino 22, 6814 Cadempino, Switzerland/CH

Entry Deleted Capital

active hare Capital CHF 250'000

Entry Deleted Activity (original Language)

active La ricerca, lo sviluppo galenico, la produzione e la commercializzazione di ogni prodotto

chimico, farmaceutico, dietetico, alimentare e cosmetico, nonché l'elaborazione delle relative tecnologie di produzione, in particolare la preparazione di dossier per la registrazione, brevetti, know-how e technology transfer. L'acquisto e la vendita di materie prime, prodotti semilavorati o finiti nel campo chimico, farmaceutico, dietetico, alimentare e cosmetico. La società potrà partecipare quale azionista a ditte similari.

(Research, development pharmaceutics, production and marketing of each product
chemical, pharmaceutical, nutritional, food and cosmetics, as well as to develop relevant technologies of production, in particular the preparation of dossiers for registration, patents, know-how and technology transfer. The purchase and sale of raw materials, semi-finished or finished products in the chemical, pharmaceutical, dietary)

Executive board

Title Name

Member Giorgio Baratelli

Investments

It is believed that the company has no investments.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.45.37
UK Pound	1	Rs.70.38
Euro	1	Rs.58.93

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.